Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Apr 16;13(4):1315.
doi: 10.3390/nu13041315.

Treatment with a Probiotic Mixture Containing Bifidobacterium animalis Subsp. Lactis BB12 and Enterococcus faecium L3 for the Prevention of Allergic Rhinitis Symptoms in Children: A Randomized Controlled Trial

Caterina Anania  1 , Vincenza Patrizia Di Marino  1 , Francesca Olivero  2 , Daniela De Canditiis  3 , Giulia Brindisi  1 , Federico Iannilli  1 , Giovanna De Castro  1 , Anna Maria Zicari  1 , Marzia Duse  1
Affiliations
Randomized Controlled Trial

Treatment with a Probiotic Mixture Containing Bifidobacterium animalis Subsp. Lactis BB12 and Enterococcus faecium L3 for the Prevention of Allergic Rhinitis Symptoms in Children: A Randomized Controlled Trial

Caterina Anania et al. Nutrients. .

Abstract

Background: Probiotics may prevent the allergic response development due to their anti-inflammatory and immunomodulatory effects. The aim of this study is to determine if the prophylactic treatment with a mixture of Bifidobacterium animalis subsp. Lactis BB12 and Enterococcus faecium L3 would reduce symptoms and need for drug use in children with allergic rhinitis (AR).

Methods: The study included 250 children aged from 6 to 17 years, affected by AR. Patients were randomly assigned to the intervention group (150) or to the placebo group (100). Patients in the intervention group, in addition to conventional therapy (local corticosteroids and/or oral antihistamines), were treated in the 3 months preceding the onset of symptoms related to the presence of the allergen to which the children were most sensitized, with a daily oral administration of a probiotic mixture containing the Bifidobacterium animalis subsp. Lactis BB12 DSM 15954 and the Enterococcus faecium L3 LMG P-27496 strain. We used Nasal Symptoms Score (NSS) to evaluate AR severity before and after the treatment with probiotics or placebo.

Results: the patients in the intervention group had a significant reduction in their NSS after probiotic treatment (p-value = 2.2 × 10-10. Moreover, for the same group of patients, we obtained a significant reduction in the intake of pharmacological therapy. In particular, we obtained a reduction in the use of oral antihistamines (p-value = 2.2 × 10-16), local corticosteroids (p-value = 2.2 × 10-13), and of both drugs (p-value 1.5 × 10-15).

Conclusions: When administered as a prophylactic treatment, a mixture of BB12 and L3 statistically decreased signs and symptoms of AR and reduced significantly the need of conventional therapy.

Keywords: Bifidobacterium animalis subsp. Lactis BB12; Enterococcus faecium L3; allergic rhinitis; children; probiotics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Boxplot of NSS before and after treatment in the intervention group (group A).
Figure 2
Figure 2
Boxplot of NSS before and after treatment in the placebo group (group B).
See this image and copyright information in PMC

References

    1. Ebert C.S., Jr., Pillsbury H.C., 3rd Epidemiology of allergy. Otolaryngol. Clin. N. Am. 2011;44:537–548. doi: 10.1016/j.otc.2011.03.001. - DOI - PubMed
    1. Dykewicz M.S., Hamilos D.L. Rhinitis and sinusitis. J. Allergy Clin. Immunol. 2010;125:S103–S115. doi: 10.1016/j.jaci.2009.12.989. - DOI - PubMed
    1. De Martinis M., Sifuro M.M., Suppa M., Ginaldi L. New prospective in food allergy. Int. J. Mol. Sci. 2020;21:1474. doi: 10.3390/ijms21041474. - DOI - PMC - PubMed
    1. Mastrorilli C., Caffarelli C., Hoffmann-Sommergruber K. Food allergy and atopic dermatitis: Prediction, progression and prevention. Pediatr. Allergy Immunol. 2017;28:831–840. doi: 10.1111/pai.12831. - DOI - PubMed
    1. Fiocchi A., Pawankar R., Cuello-Garcia C., Ahn K., Al-Hammadi S., Agarwal A., Beyer K., Burks W., Canonica G.W., Ebisawa M., et al. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. World Allergy Organ J. 2015;8:4. doi: 10.1186/s40413-015-0055-2. - DOI - PMC - PubMed

Publication types

LinkOut - more resources